This inventor holds 2 USPTO granted patents. Top assignees: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts, Medigene Ag. Active years: 2013-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 166 
2 out of 48 
Years Active: 2013-2016
Title: The Innovative Contributions of Sandra Luettgau
Introduction
Sandra Luettgau is a notable inventor based in Schongau, Germany. She has made significant contributions to the field of tumor treatment through her innovative research and development. With a total of 2 patents, her work focuses on the application of specific anti-L1 antibodies in medical treatments.
Latest Patents
One of her latest patents is titled "Treatment of tumors using specific anti-L1 antibody." This invention relates to the anti-L1 monoclonal antibody 9.3, along with related antibodies or binding molecules. The primary use of this invention is in the treatment of tumors, showcasing her commitment to advancing medical science.
Career Highlights
Throughout her career, Sandra has worked with prominent organizations such as Medigene AG and the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts. Her experience in these institutions has allowed her to contribute to groundbreaking research in cancer treatment.
Collaborations
Sandra has collaborated with esteemed colleagues, including Daniela Kelm and Peter Altevogt. These partnerships have further enriched her research and development efforts in the field of oncology.
Conclusion
Sandra Luettgau's innovative work in the treatment of tumors exemplifies her dedication to improving medical outcomes. Her contributions through patents and collaborations highlight her role as a significant figure in the field of cancer research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile